• Stevanato Group’s November 3, 2026, third-quarter earnings call featured CEO Franco Stevanato, CFO Marco Dal Lago and communications chief Lisa Miles.
• Management expects low-single-digit growth in 2027 as lower GLP-1 volumes from one customer temporarily constrain growth.
• Most affected syringe capacity has been backfilled; management expects more normalized growth in 2028 as broader biologics demand offsets the shortfall.
• Full-year 2026 guidance remains unchanged at €1.26 billion–€1.28 billion revenue and €335 million–€345.2 million adjusted EBITDA.
• Third-quarter revenue rose 8% to €326.1 million; non-GLP biologics revenue increased more than 30%, offsetting declining GLP-1 sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stevanato Group S.p.A. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-458313), on November 12, 2026, and is solely responsible for the information contained therein.